# EDGAR Filing Document

**Accession Number:** 0001285550
**File Stem:** 0001193125-26-039470
**Filing Date:** 2026-2
**Character Count:** 108933
**Document Hash:** c6f2ba55f4cb9d993a28abfcb9b0c917
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-039470.hdr.sgml**: 20260205

**ACCESSION NUMBER**: 0001193125-26-039470

**CONFORMED SUBMISSION TYPE**: 8-K/A

**PUBLIC DOCUMENT COUNT**: 36

**CONFORMED PERIOD OF REPORT**: 20251120

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260205

**DATE AS OF CHANGE**: 20260205

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ClearPoint Neuro, Inc.
- **CENTRAL INDEX KEY:** 0001285550
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 582394628
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-34822
- **FILM NUMBER:** 26603288

**BUSINESS ADDRESS:**
- **STREET 1:** 120 S. SIERRA AVENUE
- **STREET 2:** SUITE 100
- **CITY:** SOLANA BEACH
- **STATE:** CA
- **ZIP:** 92075
- **BUSINESS PHONE:** 9499006833

**MAIL ADDRESS:**
- **STREET 1:** 120 S. SIERRA AVENUE
- **STREET 2:** SUITE 100
- **CITY:** SOLANA BEACH
- **STATE:** CA
- **ZIP:** 92075

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MRI INTERVENTIONS, INC.
- **DATE OF NAME CHANGE:** 20110714

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SURGIVISION INC
- **DATE OF NAME CHANGE:** 20091106

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SURGI VISION INC
- **DATE OF NAME CHANGE:** 20040331

?xml version='1.0' encoding='ASCII'? 8-K/A

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## FORM 8-K/A

## (Amendment No. 1)

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** November 20, 2025<br>

------

CLEARPOINT NEURO, INC.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-34822 | 58-2394628 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 120 S. Sierra Ave., Suite 100 |  |  |
| Solana Beach**,** California |  | 92075 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** 888 287-9109<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Stock, $0.01 par value per share | CLPT | The Nasdaq Stock Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Explanatory Note**

On November 20, 2025, ClearPoint Neuro, Inc., a Delaware corporation (the "Company"), filed with the Securities and Exchange Commission (the "SEC") a Current Report on Form 8-K (the "Initial Form 8-K") disclosing that the Company completed its acquisition of IRRAS Holdings, Inc., a Delaware corporation ("IRRAS"), pursuant to the previously announced Agreement and Plan of Merger and Reorganization (the "Merger Agreement") with Ignite Merger Sub, Inc., a Delaware corporation and a direct wholly-owned subsidiary of the Company ("First Merger Sub"), ClearPoint Holdings, LLC, a Delaware limited liability company and a direct wholly-owned subsidiary of the Company ("Second Merger Sub"), IRRAS, the seller representative and the equityholders of IRRAS that are parties to the Merger Agreement. Pursuant to the Merger Agreement, the First Merger Sub merged with and into IRRAS (the "First Merger"), with IRRAS surviving the First Merger, and, immediately following the First Merger, IRRAS merged with and into the Second Merger Sub (the "Second Merger" and together with the First Merger, the "Merger"), with the Second Merger Sub surviving the Second Merger.

## In the Initial Form 8-K, the Company stated its intention to file the historical financial statements of IRRAS and the pro forma financial information required by parts (a) and (b) of Item 9.01 of Form 8-K not later than 71 calendar days after the date that the Initial Form 8-K was required to be filed with the SEC. Pursuant to the instructions to Item 9.01 of Form 8-K, this Amendment No. 1 to Current Report on Form 8-K/A amends the Initial Form 8-K in order to provide the required financial information, which are filed as exhibits hereto and are incorporated herein by reference.

## The unaudited pro forma condensed combined financial information included and the related notes in this Current Report on Form 8-K/A have been presented for informational purposes only, as required by the disclosure requirements of Form 8-K, and do not represent or purport to represent actual financial positions or results of operations that the Company would have achieved had the companies been combined as of the dates or during the periods presented, nor do they represent or purport to represent any anticipated combined financial position or the future results of operations that the Company may achieve after acquisition.

## Item 9.01 Financial Statements and Exhibits.
(a) Financial statements of business acquired.

The historical audited consolidated balance sheet of IRRAS as of December 31, 2024 and the related audited consolidated statements of operations, comprehensive income (loss), stockholders' equity and cash flows for the year ended December 31, 2024, and the notes related thereto, are included as Exhibit 99.1 hereto and incorporated by reference into this Item 9.01(a).

The unaudited condensed consolidated financial statements of IRRAS as of September 30, 2025 and for the nine months ended September 30, 2025 and September 30, 2024 and the related notes thereto, are included as Exhibit 99.2 hereto and incorporated by reference into this Item 9.01(a).

(b) Pro forma financial information.

The unaudited pro forma condensed combined balance sheet as of September 30, 2025, the unaudited pro forma condensed combined statement of operations for the nine months ended September 30, 2025, the unaudited pro forma condensed combined statement of operations for the year ended December 31, 2024, and the related notes thereto, are included as Exhibit 99.3 hereto and incorporated by reference into this Item 9.01(b).

(d) Exhibits.

The following exhibits are filed or furnished herewith:

------

**<u>Exhibit No.</u> <u>Description</u>**

---

| | |
|:---|:---|
| Exhibit 23.1 | [<u>Consent of Cherry Bekaert, independent registered public accounting firm for IRRAS</u>](clpt-ex23_1.htm) |
| Exhibit 99.1 | [<u>The historical audited consolidated balance sheet of IRRAS as of December 31, 2024 and the related audited consolidated statements of operations, comprehensive income (loss), stockholders' equity and cash flows for the year ended December 31, 2024, and the notes related thereto</u>](clpt-ex99_1.htm) |
| Exhibit 99.2 | [<u>The unaudited condensed consolidated financial statements of IRRAS as of September 30, 2025 and for the nine months ended September 30, 2025 and September 30, 2024 and the related notes thereto</u>](clpt-ex99_2.htm) |
| Exhibit 99.3 | [<u>The unaudited pro forma condensed combined balance sheet as of September 30, 2025, the unaudited pro forma condensed combined statement of operations for the nine months ended September 30, 2025, the unaudited pro forma condensed combined statement of operations for the year ended December 31, 2024, and the related notes thereto</u>](clpt-ex99_3.htm) |
| Exhibit 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | CLEARPOINT NEURO, INC. |
| Date: | February 5, 2026 | By:  | /s/ Danilo D'Alessandro |
|  |  |  | Danilo D'Alessandro<br>Chief Financial Officer |

---

------

## Exhibit 23.1

**Exhibit 23.1**

![img87815545_0.jpg](img87815545_0.jpg)

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the inclusion or incorporation by reference of our report, dated February 3, 2026, relating to the consolidated financial statements of IRRAS Holdings, Inc. as of and for the year ended December 31, 2024, included in this Current Report on Form 8-K/A of ClearPoint Neuro, Inc. (the "Company"), in (i) the Company's Registration Statement on Form S-8 (No. 333-183382), (ii) the Company's Registration Statement on Form S-8 (No. 333-191908), (iii) the Company's Registration Statement on Form S-8 (No. 333-206432), (iv) the Company's Registration Statement on Form S-8 (No. 333-220783), (v) the Company's Registration Statement on Form S-8 (No. 333-238907), (vi) the Company's Registration Statement on Form S-8 No. (333-256789), (vii) the Company's Registration Statement on Form S-8 (No. 333-265349), (viii) the Company's Registration Statement on Form S-3 (No. 333-275476), (ix) the Company's Registration Statement on Form S-8 (No. 333-279454), (x) the Company's Registration Statement on Form S-8 (No. 333-290033), and (xi) the Company's Registration Statement on Form S-3 (No. 333-292733).

*/s/ Cherry Bekaert LLP*

Tampa, Florida

February 5, 2026

------

-1-<br>

------

## Exhibit 99.1

**Exhibit 99.1**

**IRRAS HOLDINGS, INC. AND SUBSIDIARIES**

CONSOLIDATED FINANCIAL STATEMENTS

***As of and for the Year Ended December 31, 2024***

***And Report of Independent Auditor***

------

**IRRAS HOLDINGS, INC. AND SUBSIDIARIES**

**TABLE OF CONTENTS**

------

---

| | |
|:---|:---|
| **REPORT OF INDEPENDENT AUDITOR** | 1-2 |
| **CONSOLIDATED FINANCIAL STATEMENTS** |  |
| Consolidated Balance Sheet | &nbsp;&nbsp;&nbsp;&nbsp;3 |
| Consolidated Statement of Operations and Comprehensive Loss | &nbsp;&nbsp;&nbsp;&nbsp;4 |
| Consolidated Statement of Stockholders' Deficit | &nbsp;&nbsp;&nbsp;&nbsp;5 |
| Consolidated Statement of Cash Flows | &nbsp;&nbsp;&nbsp;&nbsp;6 |
| Notes to the Consolidated Financial Statements | &nbsp;&nbsp;&nbsp;&nbsp;7-15 |

---

------

**Report of Independent Auditor**

To the Board of Directors

IRRAS Holdings, Inc.

San Diego, California

**Opinion**

We have audited the accompanying consolidated financial statements of IRRAS Holdings, Inc. and Subsidiaries (the "Company"), which comprise the consolidated balance sheet as of December 31, 2024, and the related statements of operations and comprehensive loss, stockholders' deficit, and cash flows for the year then ended, and the related notes to the consolidated financial statements.

In our opinion, the consolidated financial statements referred to above presents fairly, in all material respects, the financial position of IRRAS Holdings, Inc. as of December 31, 2024, and the results of its operations and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

**Other Matter – Change in Control**

As discussed in Note 10 to the consolidated financial statements, the Company entered into a Merger agreement with ClearPoint Neuro, Inc. ("ClearPoint") on November 6, 2025 whereby ClearPoint acquired the Company in an all-stock and cash transaction.

**Basis for Opinion**

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Financial Statement* section of our report. We are required to be independent of IRRAS Holdings, Inc. and Subsidiaries and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

**Responsibilities of Management for the Consolidated Financial Statements**

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of the consolidated financial statements that is free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the consolidated financial statements is available to be issued.

**Auditor's Responsibilities for the Audit of the Consolidated Financial Statements**

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and, therefore, is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements, including omissions, are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statement.

------

In performing an audit in accordance with generally accepted auditing standards, we:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Exercise professional judgment and maintain professional skepticism throughout the audit.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of IRRAS Holdings, Inc.'s internal control. Accordingly, no such opinion is expressed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

/s/ Cherry Bekaert LLP

Tampa, Florida

February 3, 2026

------

**IRRAS HOLDINGS, INC. AND SUBSIDIARIES**

CONSOLIDATED BALANCE SHEET

*DECEMBER 31, 2024*

------

![img164205336_0.jpg](img164205336_0.jpg)

![img164205336_1.jpg](img164205336_1.jpg)

The accompanying notes to the consolidated financial statements is an integral part of these statements.

------

**IRRAS HOLDINGS, INC. AND SUBSIDIARIES**

CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS

*YEAR ENDED DECEMBER 31, 2024*

------

![img164205336_2.jpg](img164205336_2.jpg)

The accompanying notes to the consolidated financial statements is an integral part of these statements.

------

**IRRAS HOLDINGS, INC. AND SUBSIDIARIES**

CONSOLIDATED STATEMENT OF CHANGE IN STOCKHOLDERS' DEFICIT

*YEAR ENDED DECEMBER 31, 2024*

------

![img164205336_3.jpg](img164205336_3.jpg)

The accompanying notes to the consolidated financial statements is an integral part of these statements.

------

**IRRAS HOLDINGS, INC. AND SUBSIDIARIES**

CONSOLIDATED STATEMENT OF CASH FLOWS

*YEAR ENDED DECEMBER 31, 2024*

------

![img164205336_4.jpg](img164205336_4.jpg)

The accompanying notes to the consolidated financial statements is an integral part of these statements.

------

**IRRAS HOLDINGS, INC. AND SUBSIDIARIES**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

*DECEMBER 31, 2024* 

------

**Note 1—Description of business**

*Nature of Business and Basis of Consolidation* – The consolidated financial statements of IRRAS Holdings, Inc. and Subsidiaries (together the "Company") include the accounts of IRRAS Holdings, Inc. ("IRRAS Holdings"), IRRAS AB ("IRRAS AB"), IRRAS USA, Inc. ("IRRAS USA"), and IRRAS GmbH ("IRRAS GmbH").

IRRAS Holdings was originally incorporated as IR Holding Bidco Inc. as a Delaware corporation on June 26, 2023, for the purpose of acquiring control of IRRAS AB. In January 2024, IR Holding Bidco Inc. changed its name to IRRAS Holding, Inc. IRRAS Holdings owns 91.5% of the equity interests in IRRAS AB. IRRAS Holdings does not conduct business operations, outside of its ownership interests in IRRAS AB.

IRRAS AB was organized as a Sweden company on November 21, 2011. IRRAS AB owns 100% of the equity interests of IRRAS USA and IRRAS GmbH.

IRRAS USA was organized as a Delaware corporation on July 29, 2016, and is the entity that conducts business operations. The Company is located in San Diego, California. The Company is a commercial medical technology company focused on neurocritical care, with an emphasis on treatments for intracerebral hemorrhage, intraventricular hemorrhage, and other conditions requiring intracranial fluid management. The Company's cornerstone product is the IRRAflow system, an FDA-cleared and CE-marked platform which integrates continuous irrigation, drainage, and real-time intracranial pressure monitoring.

IRRAS GmbH was organized as a Germany company on July 14, 2016. IRRAS GmbH does not conduct business operations and was dissolved during 2025.

*Risks and Uncertainty* - The Company is subject to a number of risks and uncertainties common to biotechnology companies including competition from larger and more established companies, marketing of its products, and the uncertainty of future profitability. The Company has negative cash flows from operations of $11,393,220 for the year ended December 31, 2024, and has an accumulated deficit of $105,276,547 as of December 31, 2024. Operating results in the future could vary from the amounts derived from management's estimates and assumptions. Management has considered whether there is substantial doubt about its ability to continue as a going concern. Management believes the current cash balance, forecasted cash flows from operations, and funding from ClearPoint Neuro, Inc. ("ClearPoint") which acquired the Company during 2025, see Note 10, as necessary, are sufficient to finance the Company's continued operations for at least one year from the date of issuance of these consolidated financial statements and these consolidated financial statements have been prepared assuming that the Company will continue as a going concern.

**Note 2—Summary of significant accounting policies**

*Principles of Consolidation –* The consolidated financial statements include the accounts of IRRAS Holdings and its subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation.

The consolidated financial statements include accounts of the following companies:

---

| | | | |
|:---|:---|:---|:---|
|  | &nbsp;&nbsp;**<u>Form of Entity</u>** | &nbsp;&nbsp;**<u>Ownership</u>** | &nbsp;&nbsp;**<u>Domiciled</u>** |
| &nbsp;&nbsp;IRRAS Holdings: | &nbsp;&nbsp;Corporation |  | &nbsp;&nbsp;Delaware |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IRRAS AB: | &nbsp;&nbsp;Limited liability company | &nbsp;&nbsp;91.5% | &nbsp;&nbsp;Sweden |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IRRAS USA | &nbsp;&nbsp;Corporation | &nbsp;&nbsp;100% | &nbsp;&nbsp;Delaware |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IRRAS GmbH | &nbsp;&nbsp;Limited liability company | &nbsp;&nbsp;100% | &nbsp;&nbsp;Germany |

---

------

**IRRAS HOLDINGS, INC. AND SUBSIDIARIES**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

*DECEMBER 31, 2024* 

------

**Note 2—Summary of significant accounting policies (continued)**

*Use of Estimates* – The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results can differ from these estimates.

*Cash, Cash Equivalents, and Restricted Cash* – For purposes of the consolidated financial statement presentation, the Company considers all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company has cash pledged as collateral related to their operating lease which is classified as restricted cash. Amounts related to the cash pledged as collateral expected to be released within twelve months of the accompanying consolidated balance sheet is classified as a current asset.

*Accounts Receivable* – The Company accounts for trade receivables by adjusting the outstanding principal through charge offs and maintaining an allowance for credit losses which reserves for expected credit losses. In determining the amount of the allowance, the Company considers factors such as historical experience, creditworthiness, the age of the trade receivable balances, current economic conditions, customer-specific information and reasonable and supportable forecasts of future economic conditions. The Company makes judgments about the creditworthiness of significant customers based on ongoing credit evaluation. When the Company determines the amounts are fully uncollectible, they are written off against the allowance. Gross accounts receivable totaled $1,669,842 and $1,165,705 as of December 31, 2024 and January 1, 2024, respectively.

As of December 31, 2024, the allowance for credit losses totaled was $22,542 There were no uncollectable trade accounts receivable written-off during the year ended December 31, 2024. Net bad debt expense was $2,635 for the year ended December 31, 2024, and is included in general and administrative expense in the accompanying consolidated statement of operations and comprehensive loss.

*Inventory* – Inventory, which consist of raw materials, work in process, and finished goods available for sale, is recorded at standard cost. The standard cost is re-evaluated on a quarterly basis and adjusted if underlying assumptions change, and is valued at the lower of cost or net realizable value. This valuation requires the Company to make judgments, based on currently available information, about the likely method of disposition, and expected recoverable value of each disposition category. The inventory valuation allowance was $46,595 as of December 31, 2024.

*Equipment, Furniture, and Depreciation* – Property and equipment are stated at cost, less accumulated depreciation. Expenditures for betterments and major renewals are charged to the property and equipment accounts, while expenditures for maintenance, repairs and minor improvements are charged to expense. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is reflected in operations. Depreciation is computed over the estimated useful lives of assets using the straight-line method. Estimated useful lives used for computing deprecation is three to five years.

*Revenue Recognition* – The Company derives their revenue from the sale of medical devices. In accordance with Accounting Standards Codification ("ASC") 606, revenue is recognized upon the transfer of control of promised products to customers in amounts that reflect the consideration the Company expect to receive in exchange for those products.

------

**IRRAS HOLDINGS, INC. AND SUBSIDIARIES**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

*DECEMBER 31, 2024* 

------

**Note 2—Summary of significant accounting policies (continued)**

The Company determines the amount of revenue to be recognized through the application of the following steps:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Identification of the contract with a customer

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Identification of the performance obligations in the contract

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Determination of the transaction price

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Allocation of the transaction price to the performance obligations in the contract

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Recognition of revenue when, or as, the Company satisfies a performance obligation

The Company generates revenue through the sale of products, with standard shipping terms and discounts. The Company's revenue transactions consist of a single performance obligation to transfer promised goods. Quantities to be delivered to the customer are determined through orders received from the customer. The Company recognizes revenue when it has fulfilled the performance obligation, which is typically determined by the shipping terms. Revenue is measured as the amount of consideration the Company expects to receive in exchange for the transferred goods. Payment terms are consistent with terms standard to the market the Company serves. The Company does not offer warranties. All returns of non-disposable products must be approved by the Company.

*Income Taxes* – The Company accounts for income taxes under the asset and liability method, whereby deferred tax assets and liabilities are recorded for the future tax impact attributable to differences between the consolidated financial statements carrying amounts of existing assets and liabilities and their respective tax bases as well as expected benefits of utilizing net operating losses and credit carryforwards.

The Company measures deferred tax assets and liabilities using enacted tax rates that are expected to apply in the years in which the Company expects to recover or settle those temporary differences. The Company recognizes in income the effect of a change in tax rates on deferred tax assets and liabilities in the period that includes the enactment date.

The Company recognizes the effect of income tax positions only if sustaining those positions is more likely than not. The Company reflects changes in recognition or measurement of uncertain tax positions in the period in which a change in judgment occurs. The Company recognizes interest and penalties, if any, related to uncertain tax positions within income tax expense. Accrued interest and penalties are included within the related tax liability line in the accompanying consolidated balance sheet.

The Company evaluates the need to establish a valuation allowance based upon expected levels of taxable income, future reversals of existing temporary differences, tax planning strategies and recent financial operations. The Company establishes a valuation allowance to reduce deferred tax assets to the extent it is more likely than not that some or all of the deferred tax assets will not be realized.

*Advertising and Marketing* – The Company expenses advertising and marketing costs as they are incurred. Total costs for the year ended December 31, 2024 was $459,633, which is included in sales and marketing expense in the accompanying consolidated statement of operations and comprehensive loss.

*Research and Development Costs* – Expenditures for research and development activities include costs incurred for experimentation, design, and testing and are expensed as incurred. Research and development expense was $839,149 for the year ended December 31, 2024, which is included in research and development expense in the accompanying consolidated statement of operations and comprehensive loss.

------

**IRRAS HOLDINGS, INC. AND SUBSIDIARIES**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

*DECEMBER 31, 2024* 

------

**Note 2—Summary of significant accounting policies (continued)**

*Lease Accounting Policy* – The Company leases office space in San Diego, California. The Company determines whether a contract contains a lease at inception by determining if the contract conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The Company has a lease agreement with lease and non-lease components, which are generally accounted for separately with amounts allocated to the lease and non-lease components based on relative stand-alone prices.

Operating right-of-use assets and operating lease liabilities are recognized at the commencement date based on the present value of the future minimum lease payments over the lease term. Renewal and termination clauses are factored into the determination of the lease term, if it is reasonably certain these options would be exercised by the Company. Lease assets are amortized over the lease term, unless there is a transfer of title or purchase option reasonably certain of exercise, in which case the asset life is used. In order to determine the present value of lease payments, the Company estimated their incremental borrowing rate to calculate lease assets and liabilities.

The Company's lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company has no material obligation for leases signed but not yet commenced as of December 31, 2024. The Company does not have any sublease activities. The Company elected to apply the short term lease measurement and recognition exemption to its leases where appliable.

*Foreign Currency Translation Adjustments –* IRRAS AB, located in Sweden, uses the local currency as its functional currency. The local currency was the Swedish Krona for the year ended December 31, 2024. Assets and liabilities of IRRAS AB are translated to the reporting currency (U.S. dollars) based on the current exchange rate in effect at the consolidated balance sheet date. IRRAS AB income and expenses are translated at average rates for the year presented. IRRAS GmbH, located in Germany, uses the local currency as its functional currency. The local currency was the Euro for the year ended December 31, 2024. Assets and liabilities of IRRAS GmbH are translated to the reporting currency (U.S. dollars) based on the current exchange rate in effect at the consolidated balance sheet date. IRRAS GmbH income and expenses are translated at average rates for the year presented.

**Note 3—Equipment and furniture**

Equipment and furniture consist of the following as of December 31, 2024:

![img164205336_5.jpg](img164205336_5.jpg)

------

**IRRAS HOLDINGS, INC. AND SUBSIDIARIES**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

*DECEMBER 31, 2024* 

------

**Note 4—Convertible promissory note**

During 2024, the Company entered into convertible promissory notes ("2024 Convertible Notes") with certain investors in exchange for an aggregate principal amount of $6,330,203. The 2024 Convertible Notes accrue simple interest at a rate of 5% per annum and mature in October 2025, unless otherwise converted. The 2024 Convertible Notes are automatically convertible upon the completion of a qualified financing, as defined in the convertible promissory note agreements. The 2024 Convertible Notes convert into the same class and series of capital stock of the Company issued to other investors in the qualified financing. The amount of shares received upon conversion is determined by dividing the unpaid principal amount plus related interest on the date of conversion by a conversion price equal to the lower of: (a) 85% of the price per share, or (b) the price per share that results when $34,000,000 is divided by the fully diluted capitalization as defined in the convertible promissory note agreements, as of immediately prior to the initial closing of such qualified financing. As of December 31, 2024, the principal balance of the 2024 Convertible Notes was $6,330,203. Interest accrued on the 2024 Convertible Notes was $68,727 for the year ended December 31, 2024. Interest expense totaled $68,727 as of December 31, 2024.

The Company concluded that the 2024 Convertible Notes have an embedded derivative that did not require bifurcation and qualifies for the fair value option under current accounting guidance. The Company elected to account for the 2024 Convertible Notes using the fair value option, which requires the Company to record changes in fair value as a component of other income or expense. The fair value of the 2024 Convertible Notes as of December 31, 2024 was $6,549,806, which resulted in the recognition of an other expense of $219,603 from the change in the fair value of the 2024 Convertible Notes on the Company's accompanying consolidated statement of operations and comprehensive loss. The fair value of the 2024 Convertible Notes was estimated using the risky bond plus call coupled with a probability weighted expected return method. The significant assumptions as of December 31, 2024 are as followed:

![img164205336_6.jpg](img164205336_6.jpg)

**Note 5—Capital structure**

In accordance with the Company's Amendment to Certificate of Incorporation dated September 15, 2023, the Company is authorized to issue 3,000,000 shares of $0.0001 par value common stock. There were 1,835,095 shares of common stock issued and outstanding at December 31, 2024.

The business and affairs of the Company shall be managed by or under the direction of the board of directors. The board of directors is expressly authorized to adopt, amend, alter, or repeal the by-laws of the Company.

------

**IRRAS HOLDINGS, INC. AND SUBSIDIARIES**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

*DECEMBER 31, 2024* 

------

**Note 6—Commitments and contingencies**

*Operating Lease* – In March 2023, the Company entered into an operating lease agreement for its U.S. office space in San Diego, California. The lease commencement date was January 1, 2024 (the "2023 Lease"). The 2023 Lease is set to expire in April 2031. The 2023 Lease contains provisions for free rent and future rent increases along with a $1,000,000 letter of credit subject to adjustments, as defined in the operating lease agreement.

Total fixed operating lease expense for the year ended December 31, 2024 was $626,029.

Future minimum payments under the operating lease for the year ended December 31, 2024 are as follows:

![img164205336_7.jpg](img164205336_7.jpg)

As of December 31, 2024, other information related to the leases was as follows:

![img164205336_8.jpg](img164205336_8.jpg)

**Note 7—Income taxes**

The components of income tax provision from continued operations for the year ended December 31, 2024 are as follows:

![img164205336_9.jpg](img164205336_9.jpg)

------

**IRRAS HOLDINGS, INC. AND SUBSIDIARIES**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

*DECEMBER 31, 2024* 

------

**Note 7—Income taxes (continued)**

The significant components of deferred tax assets and liabilities as of December 31, 2024 are as follows:

![img164205336_10.jpg](img164205336_10.jpg)

The Company has determined it is more likely than not that its deferred tax assets will not be realized. Accordingly, a valuation allowance has been recorded at December 31, 2024 to fully offset the deferred tax asset of $34,042,351.

As of December 31, 2024, the Company had approximately $81,427,000 of net operating loss carryforwards available for federal tax purposes of which $80,712,000 were generated after 2017 and do not expire. As of December 31, 2024, the Company also had approximately $715,000 of net operating loss carryforwards that will begin to expire in 2036. As of December 31, 2024, the Company also had approximately $45,743,000 of net operating loss carryforwards in various states. The state net operating loss carryforwards begin to expire based on state specific rules. In addition, as of December 31, 2024, the Company had foreign net operating loss carryforwards which begin to expire in 2036.

Utilization of the net operating loss carryforwards may be subject to a substantial annual limitation due to ownership change limitations that may have occurred or that could occur in the future, as required by Section 382 of the Internal Revenue Code of 1986, as amended, as well as similar state provisions. These ownership changes may limit the amount of the net operating loss carryover that can be utilized annually to offset future taxable income. In general, an "ownership change" as defined by Section 382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders.

The Company has not completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since the Company's formation due to the complexity and cost associated with such a study, and the fact that there may be additional such ownership changes in the future.

The Company has no unrecognized tax benefits. It is not anticipated that there will not be a significant change in unrecognized tax benefits over the next 12 months.

------

**IRRAS HOLDINGS, INC. AND SUBSIDIARIES**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

*DECEMBER 31, 2024* 

------

**Note 7—Income taxes (continued)**

The Company and its subsidiaries are subject to U.S. federal and state income tax, and in the normal course of business, its income tax returns are subject to examination by the relevant taxing authorities. As of December 31, 2024, the 2020 – 2024 tax years remain subject to examination in the U.S. federal tax and various state tax jurisdictions. However, to the extent allowed by law, the taxing authorities may have the right to examine the period from inception through 2024 where net operating losses and income tax credits were generated and carried forward and make adjustments to the amount of the net operating loss and income tax credit carryforward amount. The Company is not currently under examination by federal or state jurisdictions.

The Company recorded deferred tax assets during the year related to net operating loss carryforwards and capitalized research costs under IRC 174. Because the Company does not have sufficient positive evidence to conclude that these deferred tax assets are realizable, the deferred tax assets were fully offset by a corresponding valuation allowance.

The Company has identified that Form 5471, *Information Return of U.S. Persons With Respect to Certain Foreign Corporations*, was not timely filed for certain foreign subsidiaries for prior tax years. Failure to file Form 5471 may subject the Company to penalties of up to $10,000 per form per year. The Company is currently evaluating its eligibility for relief under the reasonable cause provisions of the Internal Revenue Code. At this time, the Company cannot reasonably estimate the outcome or amount of any potential penalty assessment. Accordingly, no liability has been recorded related to this matter as of December 31, 2024.

**Note 8—401(k) plan**

The Company maintains a 401(k) plan (the "Plan") for all eligible employees. The Company has not made contributions to the Plan during the year ended December 31, 2024.

**Note 9—Concentrations of credit risk**

The Company maintains its cash in bank deposit accounts that, at times, may exceed federally insured limits. The Federal Deposit Insurance Corporation provides a $250,000 guarantee per depositor for accounts held at insured banks. At December 31, 2024, the Company had $2,611,821 uninsured bank deposits. Management believes the Company is not exposed to significant credit risk in these accounts.

**Note 10—Subsequent events**

The Company has evaluated all subsequent events through February 3, 2026, the date the consolidated financial statements were available to be issued and determined no additional subsequent events had occurred that would require disclosure in the consolidated financial statements, except as discussed below.

*Issuance of Convertible Promissory Notes* – During 2025, the Company entered into convertible promissory notes (the "2025 Convertible Notes") for total proceeds of $7,685,000.

*Amendment of Convertible Promissory Notes* – In September 2025, the Company entered into an omnibus amendment to the 2024 Convertible Notes and 2025 Convertible Notes to extend the maturity date from October 1, 2025 to October 1, 2026.

------

**IRRAS HOLDINGS, INC. AND SUBSIDIARIES**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

*DECEMBER 31, 2024* 

------

**Note 10—Subsequent events (continued)**

*Stock Conversion* – During May 2025, the Company executed a stock conversion in which all 1,835,095 shares of common stock outstanding were converted into 18,350,950 shares of series seed preferred stock (the "Preferred Stock"). The holders of Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of common stock into which the shares of Preferred Stock could be converted as of the record date for determining stockholders entitled to vote. The Preferred Stock has non-cumulative dividends. Each share of Preferred Stock shall be convertible, at the option of the holder thereof, at any time after the date of issuance of such shares, into such number of fully paid and non-assessable shares of common stock as determined and defined in the amended and restated articles of incorporation. In the event of liquidation, the holders of Preferred Stock shall be entitled to receive liquidation proceeds in preference to the holders of common stock. The Preferred Stock is not redeemable.

*Dissolution of IRRAS GmbH* – In August 2025, IRRAS GmbH was formally dissolved and became inactive.

*Squeeze-Out Payment –* Immediately before the acquisition by ClearPoint Neuro, Inc. detailed below, the Company paid approximately $2,200,000 to complete the squeeze-out of the remaining minority shareholders of IRRAS AB.

*Acquisition by ClearPoint Neuro, Inc.* – On November 6, 2025, the Company entered into a Merger agreement with ClearPoint Neuro, Inc. ("ClearPoint") whereby ClearPoint acquired the Company in an all-stock and cash transaction. Under the terms of the agreement, the Company's stockholders will receive $5 million in cash and 1,325,000 shares of ClearPoint common stock at closing. As additional consideration for the Company's stockholders, the merger agreement provides for ClearPoint to pay earnout consideration during three one-year earnout periods equal to 25% of net sales of certain the Company's products above certain thresholds. All convertible notes and related interest noted above were automatically converted into common stock of IRRAS Holdings, Inc. immediately before the closing of the transaction.

------

## Exhibit 99.2

**Exhibit 99.2**

**IRRAS HOLDINGS, INC. AND SUBSIDIARIES** 

CONSOLIDATED BALANCE SHEETS

*AS OF SEPTEMBER 30, 2025 (UNAUDITED) AND DECEMBER 31, 2024*

------

![img165128857_0.jpg](img165128857_0.jpg)

![img165128857_1.jpg](img165128857_1.jpg)

The accompanying notes to the consolidated financial statements are an integral part of these statements.

------

**IRRAS HOLDINGS, INC. AND SUBSIDIARIES**

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

*FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025 AND SEPTEMBER 30, 2024 (UNAUDITED)*

------

![img165128857_2.jpg](img165128857_2.jpg)

The accompanying notes to the consolidated financial statements are an integral part of these statements.

------

**IRRAS HOLDINGS, INC. AND SUBSIDIARIES**

CONSOLIDATED STATEMENTS OF CASH FLOWS

*FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025 AND SEPTEMBER 30, 2024 (UNAUDITED)*

------

![img165128857_3.jpg](img165128857_3.jpg)

The accompanying notes to the consolidated financial statements are an integral part of these statements.

------

**IRRAS HOLDINGS, INC. AND SUBSIDIARIES**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

*SEPTEMBER 30, 2025 (UNAUDITED) AND DECEMBER 31, 2024*

------

**Note 1—Description of business**

*Nature of Business and Basis of Consolidation* – The consolidated financial statements of IRRAS Holdings, Inc. and Subsidiaries (together the "Company") include the accounts of IRRAS Holdings, Inc. ("IRRAS Holdings"), IRRAS AB ("IRRAS AB"), IRRAS USA, Inc. ("IRRAS USA"), and IRRAS GmbH ("IRRAS GmbH").

IRRAS Holdings was originally incorporated as IR Holding Bidco Inc. as a Delaware corporation on June 26, 2023, for the purpose of acquiring control of IRRAS AB. In January 2024, IR Holding Bidco Inc. changed its name to IRRAS Holding, Inc. IRRAS Holdings owns 91.5% of the equity interests in IRRAS AB. IRRAS Holdings does not conduct business operations, outside of its ownership interests in IRRAS AB.

IRRAS AB was organized as a Sweden company on November 21, 2011. IRRAS AB owns 100% of the equity interests of IRRAS USA and IRRAS GmbH.

IRRAS USA was organized as a Delaware corporation on July 29, 2016, and is the entity that conducts business operations. The Company is located in San Diego, California. The Company is a commercial medical technology company focused on neurocritical care, with an emphasis on treatments for intracerebral hemorrhage, intraventricular hemorrhage, and other conditions requiring intracranial fluid management. The Company's cornerstone product is the IRRAflow system, an FDA-cleared and CE-marked platform which integrates continuous irrigation, drainage, and real-time intracranial pressure monitoring.

IRRAS GmbH was organized as a Germany company on July 14, 2016. IRRAS GmbH does not conduct business operations and was dissolved during the period ended September 30, 2025.

*Risks and Uncertainty* – The Company is subject to a number of risks and uncertainties common to biotechnology companies including competition from larger and more established companies, marketing of its products, and the uncertainty of future profitability. The Company has negative cash flows from operations of $6,418,826 for the nine months ended September 30, 2025, and has an accumulated deficit of $112,575,919 as of September 30, 2025. Operating results in the future could vary from the amounts derived from management's estimates and assumptions. Management has considered whether there is substantial doubt about its ability to continue as a going concern. Management believes the current cash balance, forecasted cash flows from operations, and funding from ClearPoint Neuro, Inc. ("ClearPoint") which acquired the Company during November 2025, see Note 10, as necessary, are sufficient to finance the Company's continued operations for at least one year from the date of issuance of these consolidated financial statements and these consolidated financial statements have been prepared assuming that the Company will continue as a going concern.

**Note 2—Summary of significant accounting policies**

*Principles of Consolidation –* The consolidated financial statements include the accounts of IRRAS Holdings and its subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation.

------

**IRRAS HOLDINGS, INC. AND SUBSIDIARIES**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

*SEPTEMBER 30, 2025 (UNAUDITED) AND DECEMBER 31, 2024*

------

**Note 2—Summary of significant accounting policies (continued)**

*Basis of Presentation –* In the opinion of management, the accompanying unaudited condensed consolidated financial statements have been prepared on a basis consistent with the Company's December 31, 2024 audited financial statements, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth therein. These condensed consolidated financial statements have been prepared in accordance with SEC rules for interim financial information, and, therefore, omit certain information and footnote disclosures necessary to present such statements in accordance with accordance with accounting principles generally accepted in the United States ("U.S. GAAP"). The preparation of these condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto. The accompanying condensed balance sheet as of December 31, 2024 has been derived from the audited financial statements at that date but does not include all information and footnotes required by U.S. GAAP for a complete set of financial statements. The results of operations for the nine months ended September 30, 2025, may not be indicative of the results to be expected for the entire year or any future periods.

The consolidated financial statements include accounts of the following companies:

---

| | | | |
|:---|:---|:---|:---|
|  | &nbsp;&nbsp;**<u>Form of Entity</u>** | &nbsp;&nbsp;**<u>Ownership</u>** | &nbsp;&nbsp;**<u>Domiciled</u>** |
| &nbsp;&nbsp;IRRAS Holdings: | &nbsp;&nbsp;Corporation |  | &nbsp;&nbsp;Delaware |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; IRRAS AB: | &nbsp;&nbsp;Limited liability company | &nbsp;&nbsp;91.5% | &nbsp;&nbsp;Sweden |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IRRAS USA: | &nbsp;&nbsp;Corporation | &nbsp;&nbsp;100% | &nbsp;&nbsp;Delaware |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IRRAS GmbH: | &nbsp;&nbsp;Limited liability company | &nbsp;&nbsp;100% | &nbsp;&nbsp;Germany |

---

*Use of Estimates* – The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results can differ from these estimates.

*Cash, Cash Equivalents, and Restricted Cash* – For purposes of the consolidated financial statement presentation, the Company considers all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company has cash pledged as collateral related to their operating lease which is classified as restricted cash. Amounts related to the cash pledged as collateral expected to be released within twelve months of the accompanying consolidated balance sheet is classified as a current asset.

*Accounts Receivable* – The Company accounts for trade receivables by adjusting the outstanding principal through charge offs and maintaining an allowance for credit losses which reserves for expected credit losses. In determining the amount of the allowance, the Company considers factors such as historical experience, creditworthiness, the age of the trade receivable balances, current economic conditions, customer-specific information and reasonable and supportable forecasts of future economic conditions. The Company makes judgments about the creditworthiness of significant customers based on ongoing credit evaluation. When the Company determines the amounts are fully uncollectible, they are written off against the allowance. Gross accounts receivable totaled $2,193,324, $1,669,842, $1,501,842, and $1,165,705 as of September 30, 2025, January 1, 2025, September 30, 2024, and January 1, 2024, respectively.

As of September 30, 2025, September 30, 2024, and December 31, 2024, the allowance for credit losses totaled $61,441, $63,310, and $22,542, respectively. There were no uncollectable trade accounts receivable written-off during the nine months ended September 30, 2025 or the year ended December 31, 2024.

------

**IRRAS HOLDINGS, INC. AND SUBSIDIARIES**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

*SEPTEMBER 30, 2025 (UNAUDITED) AND DECEMBER 31, 2024*

------

**Note 2—Summary of significant accounting policies (continued)**

*Inventory* – Inventory, which consist of raw materials, work in process, and finished goods available for sale, is recorded at standard cost. The standard cost is re-evaluated on a quarterly basis and adjusted if underlying assumptions change, and is valued at the lower of cost or net realizable value. This valuation requires the Company to make judgments, based on currently available information, about the likely method of disposition, and expected recoverable value of each disposition category. The inventory valuation allowance was $46,607 and $46,595 as of September 30, 2025 and December 31, 2024, respectively.

*Equipment, Furniture, and Depreciation* – Property and equipment are stated at cost, less accumulated depreciation. Expenditures for betterments and major renewals are charged to the property and equipment accounts, while expenditures for maintenance, repairs and minor improvements are charged to expense. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is reflected in operations. Depreciation is computed over the estimated useful lives of assets using the straight-line method. Estimated useful lives used for computing deprecation is three to five years.

*Revenue Recognition* – The Company derives their revenue from the sale of medical devices. In accordance with Accounting Standards Codification ("ASC") 606, revenue is recognized upon the transfer of control of promised products to customers in amounts that reflect the consideration the Company expect to receive in exchange for those products.

The Company determines the amount of revenue to be recognized through the application of the following steps:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Identification of the contract with a customer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Identification of the performance obligations in the contract.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Determination of the transaction price.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Allocation of the transaction price to the performance obligations in the contract.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Recognition of revenue when, or as, the Company satisfies a performance obligation.

The Company generates revenue through the sale of products, with standard shipping terms and discounts. The Company's revenue transactions consist of a single performance obligation to transfer promised goods. Quantities to be delivered to the customer are determined through orders received from the customer. The Company recognizes revenue when it has fulfilled the performance obligation, which is typically determined by the shipping terms. Revenue is measured as the amount of consideration the Company expects to receive in exchange for the transferred goods. Payment terms are consistent with terms standard to the market the Company serves. The Company does not offer warranties. All returns of non-disposable products must be approved by the Company.

*Income Taxes* – The Company accounts for income taxes under the asset and liability method, whereby deferred tax assets and liabilities are recorded for the future tax impact attributable to differences between the consolidated financial statements carrying amounts of existing assets and liabilities and their respective tax bases as well as expected benefits of utilizing net operating losses and credit carryforwards.

The Company measures deferred tax assets and liabilities using enacted tax rates that are expected to apply in the years in which the Company expects to recover or settle those temporary differences. The Company recognizes in income the effect of a change in tax rates on deferred tax assets and liabilities in the period that includes the enactment date.

------

**IRRAS HOLDINGS, INC. AND SUBSIDIARIES**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

*SEPTEMBER 30, 2025 (UNAUDITED) AND DECEMBER 31, 2024*

------

**Note 2—Summary of significant accounting policies (continued)**

The Company recognizes the effect of income tax positions only if sustaining those positions is more likely than not. The Company reflects changes in recognition or measurement of uncertain tax positions in the period in which a change in judgment occurs. The Company recognizes interest and penalties, if any, related to uncertain tax positions within income tax expense. Accrued interest and penalties are included within the related tax liability line in the accompanying consolidated balance sheets.

The Company evaluates the need to establish a valuation allowance based upon expected levels of taxable income, future reversals of existing temporary differences, tax planning strategies and recent financial operations. The Company establishes a valuation allowance to reduce deferred tax assets to the extent it is more likely than not that some or all of the deferred tax assets will not be realized.

*Advertising and Marketing* – The Company expenses advertising and marketing costs as they are incurred. Total costs for the nine months ended September 30, 2025 and September 30, 2024 were $279,799 and $364,181, respectively, and are included in sales and marketing expense in the accompanying consolidated statements of operations and comprehensive loss.

*Research and Development Costs* – Expenditures for research and development activities include costs incurred for experimentation, design, and testing and are expensed as incurred. Research and development expense were $584,797 and $487,114 for the nine months ended September 30, 2025 and September 30, 2024, respectively, and are included in research and development expense in the accompanying consolidated statements of operations and comprehensive loss.

*Lease Accounting Policy* – The Company leases office space in San Diego, California. The Company determines whether a contract contains a lease at inception by determining if the contract conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The Company has a lease agreement with lease and non-lease components, which are generally accounted for separately with amounts allocated to the lease and non-lease components based on relative stand-alone prices.

Operating right-of-use assets and operating lease liabilities are recognized at the commencement date based on the present value of the future minimum lease payments over the lease term. Renewal and termination clauses are factored into the determination of the lease term, if it is reasonably certain these options would be exercised by the Company. Lease assets are amortized over the lease term, unless there is a transfer of title or purchase option reasonably certain of exercise, in which case the asset life is used. In order to determine the present value of lease payments, the Company estimated their incremental borrowing rate to calculate lease assets and liabilities.

The Company's lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company has no material obligation for leases signed but not yet commenced as of September 30, 2025. The Company does not have any sublease activities. The Company elected to apply the short-term lease measurement and recognition exemption to its leases where applicable.

*Foreign Currency Translation Adjustments –* IRRAS AB, located in Sweden, uses the local currency as its functional currency. The local currency was the Swedish Krona for the nine months ended September 30, 2025 and September 30, 2024. Assets and liabilities of IRRAS AB are translated to the reporting currency (U.S. dollars) based on the current exchange rate in effect at the consolidated balance sheet date. IRRAS AB income and expenses are translated at average rates for the year presented. IRRAS GmbH, located in Germany, uses the local currency as its functional currency. The local currency was the Euro during the periods for the nine months ended September 30, 2025 and September 30, 2024. Assets and liabilities of IRRAS GmbH are translated to the reporting currency (U.S. dollars) based on the current exchange rate in effect at the consolidated balance sheet date. IRRAS GmbH income and expenses are translated at average rates for the year presented.

------

**IRRAS HOLDINGS, INC. AND SUBSIDIARIES**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

*SEPTEMBER 30, 2025 (UNAUDITED) AND DECEMBER 31, 2024*

------

**Note 3—Equipment and furniture**

Equipment and furniture consist of the following as of September 30, 2025 and December 31, 2024:

![img165128857_4.jpg](img165128857_4.jpg)

**Note 4—Convertible promissory note**

During 2024, the Company entered into convertible promissory notes ("Convertible Notes") with certain investors in exchange for an aggregate principal amount of $6,330,203. The Convertible Notes accrue simple interest at a rate of 5% per annum and mature in October 2025, unless otherwise converted. The Convertible Notes are automatically convertible upon the completion of a qualified financing, as defined in the convertible promissory note agreements. The Convertible Notes convert into the same class and series of capital stock of the Company issued to other investors in qualified financing. The amount of shares received upon conversion is determined by dividing the unpaid principal amount plus related interest on the date of conversion by a conversion price equal to the lower of: (a) 65% of the price per share, or (b) the price per share that results when $34,000,000 is divided by the fully diluted capitalization as defined in the convertible promissory note agreements, as of immediately prior to the initial closing of such qualified financing. As of December 31, 2024, the principal balance of the Convertible Notes was $6,330,203.

During 2025, the Company obtained additional Convertible Notes with certain investors in exchange for an aggregate principal amount of $4,655,000. As of September 30, 2025, the principal balance of the Convertible Notes was $10,985,203.

Interest accrued on the Convertible Notes as of September 30, 2025 and December 31, 2024 were $378,028 and $68,727, respectively. Interest expense totaled $309,301 and $18,801 for the nine months ended September 30, 2025 and September 30, 2024, respectively.

In September 2025, the Company entered into an omnibus amendment to the Convertible Notes to extend the maturity date from October 1, 2025 to October 1, 2026.

The Company concluded that the Convertible Notes have an embedded derivative that did not require bifurcation and qualifies for the fair value option under current accounting guidance. The Company elected to account for the Convertible Notes using the fair value option, which requires the Company to record changes in fair value as a component of other income or expense. The fair value of the Convertible Notes as of September 30, 2025 and December 31, 2024 was $10,985,203 and $6,549,806, respectively, which resulted in the recognition of an other expense (income) of $(219,603) and $78,055 for the nine months ended September 30, 2025 and September 30, 2024, respectively, from the change in the fair value of the Convertible Notes on the Company's accompanying consolidated statements of operations and comprehensive loss. The fair value of the Convertible Notes was estimated using the risky bond plus call coupled with a probability weighted expected return method.

------

**IRRAS HOLDINGS, INC. AND SUBSIDIARIES**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

*SEPTEMBER 30, 2025 (UNAUDITED) AND DECEMBER 31, 2024*

------

**Note 4—Convertible promissory note (continued)**

The significant assumptions as of September 30, 2025 and December 31, 2024 are as follows:

![img165128857_5.jpg](img165128857_5.jpg)

**Note 5—Capital structure**

*Conversion of Common Stock* – In May 2025, all 1,835,095 outstanding shares of $0.0001 par value of the Company's common stock were automatically converted into ten (10) validly issued, fully paid and non-assessable shares of series seed preferred stock (the "Preferred Stock") in accordance with the Company's governing documents. As a result of this automatic conversion, all 1,835,095 outstanding shares of common stock were converted into 18,350,950 shares of Preferred Stock, each with a par value of $0.0001.

*Common Stock* – In accordance with the Company's Amendment to Certificate of Incorporation (the "ARCI") dated May 2, 2025, the Company is authorized to issue 22,000,000 shares of $0.0001 par value common stock. There were -0- and 184 shares of common stock issued and outstanding at September 30, 2025 and December 31, 2024, respectively.

*Preferred Stock* – In accordance with the ARCI, dated May 2, 2025, the Company is authorized to issue 18,350,950 shares of $0.0001 par value Preferred Stock.

The business and affairs of the Company shall be managed by or under the direction of the board of directors. The board of directors is expressly authorized to adopt, amend, alter, or repeal the by-laws of the Company.

The holders of Preferred Stock have various rights and preferences as follows.

*Voting –* The holders of Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of common stock into which the shares of preferred could be converted as of the record date for determining stockholders entitled to vote.

*Dividends –* Except for distributions on common stock in the form of additional common stock or other securities and rights convertible into or entitling the holder thereof to receive additional shares of common stock, any dividend or distribution shall be distributed among all holders Preferred Stock in proportion to the number of shares of common stock that would be held by each such holder if all shares of Preferred Stock were converted to common stock at the then effective conversion rate, as defined in the ARCI.

*Conversion –* Each share of Preferred Stock shall be convertible, at the option of the holder thereof, at any time after the date of issuance of such shares, into such number of fully paid and non-assessable shares of common stock as is determined by dividing (i) in the case of Preferred Stock, the series seed original issue price, as defined in the ARCI, by the series seed conversion price, as defined, both originally $1.194 per share.

------

**IRRAS HOLDINGS, INC. AND SUBSIDIARIES**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

*SEPTEMBER 30, 2025 (UNAUDITED) AND DECEMBER 31, 2024*

------

**Note 5—Capital structure (continued)**

*Liquidation* – In the event of liquidation, the holders of each series of Preferred Stock shall be entitled to receive liquidation proceeds in preference to holders of the common stock. The holders of Preferred Stock shall be entitled to receive an amount equal to the sum of the applicable original issue price, as defined in the ARCI, for such series of Preferred Stock, plus declared but unpaid dividends on such shares. If upon any such liquidation, the proceeds available for distribution to the holders of Preferred Stock shall be insufficient to pay the stockholders the full amount to which they shall be entitled, the holders of Preferred Stock shall share ratably in any distributions of the proceeds available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full.

*Redemption* – The Company's Preferred Stock is not redeemable.

**Note 6—Commitments and contingencies**

*Operating Lease* – In March 2023, the Company entered into an operating lease agreement for its U.S. office space in San Diego, California. The lease commencement date was January 1, 2024 (the "2023 Lease"). The 2023 Lease is set to expire in April 2031. The 2023 Lease contains provisions for free rent and future rent increases along with a $1,000,000 letter of credit subject to adjustments, as defined in the operating lease agreement.

Total fixed operating lease expense for the nine months ended September 30, 2025 and September 30, 2024 was $469,522 in both periods.

Future minimum payments under the operating lease as of September 30, 2025 are as follows:

![img165128857_6.jpg](img165128857_6.jpg)

As of September 30, 2025 and December 31, 2024, other information related to the leases was as follows:

![img165128857_7.jpg](img165128857_7.jpg)

------

**IRRAS HOLDINGS, INC. AND SUBSIDIARIES**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

*SEPTEMBER 30, 2025 (UNAUDITED) AND DECEMBER 31, 2024*

------

**Note 7—Income taxes**

The components of income tax provision from continued operations for the nine months ended September 30, 2025 and September 30, 2024 are as follows:

![img165128857_8.jpg](img165128857_8.jpg)

The significant components of deferred tax assets and liabilities as of September 30, 2025 and December 31, 2024 are as follows:

![img165128857_9.jpg](img165128857_9.jpg)

The Company has determined it is more likely than not that its deferred tax assets will not be realized. Accordingly, a valuation allowance has been recorded at September 30, 2025 and December 31, 2024 to fully offset the deferred tax asset of $35,031,152 and $34,042,351, respectively.

As of September 30, 2025, the Company had approximately $87,397,000 of net operating loss carryforwards available for federal tax purposes of which $86,682,000 were generated after 2017 and do not expire. As of September 30, 2025, the Company also had approximately $715,000 of net operating loss carryforwards that will begin to expire in 2036. As of September 30, 2025, the Company also had approximately $52,477,000 of net operating loss carryforwards in various states. The state net operating loss carryforwards begin to expire based on state specific rules. In addition, as of September 30, 2025, the Company had foreign net operating loss carryforwards which begin to expire in 2036.

------

**IRRAS HOLDINGS, INC. AND SUBSIDIARIES**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

*SEPTEMBER 30, 2025 (UNAUDITED) AND DECEMBER 31, 2024*

------

**Note 7—Income taxes (continued)**

Utilization of the net operating loss carryforwards may be subject to a substantial annual limitation due to ownership change limitations that may have occurred or that could occur in the future, as required by Section 382 of the Internal Revenue Code of 1986, as amended, as well as similar state provisions. These ownership changes may limit the amount of the net operating loss carryover that can be utilized annually to offset future taxable income. In general, an "ownership change" as defined by Section 382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders.

The Company has not completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since the Company's formation due to the complexity and cost associated with such a study, and the fact that there may be additional such ownership changes in the future.

The Company has no unrecognized tax benefits. It is not anticipated that there will not be a significant change in unrecognized tax benefits over the next 12 months.

The Company and its subsidiaries are subject to U.S. federal and state income tax, and in the normal course of business, its income tax returns are subject to examination by the relevant taxing authorities. As of September 30, 2025, the 2020 – 2025 tax years remain subject to examination in the U.S. federal tax and various state tax jurisdictions. However, to the extent allowed by law, the taxing authorities may have the right to examine the period from inception through 2025 where net operating losses and income tax credits were generated and carried forward and make adjustments to the amount of the net operating loss and income tax credit carryforward amount. The Company is not currently under examination by federal or state jurisdictions.

The Company recorded deferred tax assets during the year related to net operating loss carryforwards and capitalized research costs under IRC 174. Because the Company does not have sufficient positive evidence to conclude that these deferred tax assets are realizable, the deferred tax assets were fully offset by a corresponding valuation allowance.

The Company has identified that Form 5471, *Information Return of U.S. Persons With Respect to Certain Foreign Corporations*, was not timely filed for certain foreign subsidiaries for prior tax years. Failure to file Form 5471 may subject the Company to penalties of up to $10,000 per form per year. The Company is currently evaluating its eligibility for relief under the reasonable cause provisions of the Internal Revenue Code. At this time, the Company cannot reasonably estimate the outcome or amount of any potential penalty assessment. Accordingly, no liability has been recorded related to this matter as of September 30, 2025 or December 31, 2024.

**Note 8—401(k) plan**

The Company maintains a 401(k) plan (the "Plan") for all eligible employees. The Company has not made contributions to the Plan during the nine months ended September 30, 2025 and September 30, 2024.

*Uninsured Cash* – The Company maintains its cash in bank deposit accounts that, at times, may exceed federally insured limits. The Federal Deposit Insurance Corporation provides a $250,000 guarantee per depositor for accounts held at insured banks. At September 30, 2025, the Company had $1,060,231 uninsured bank deposits. Management believes the Company is not exposed to significant credit risk in these accounts.

------

**IRRAS HOLDINGS, INC. AND SUBSIDIARIES**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

*SEPTEMBER 30, 2025 (UNAUDITED) AND DECEMBER 31, 2024*

------

**Note 9—Concentrations**

*Major Customers* – For the nine months ended September 30, 2025, two customers accounted for 25% of the Company's sales. As of September 30, 2025, there were two customers who accounted for 25% of the Company's accounts receivable.

**Note 10—Subsequent events**

The Company has evaluated all subsequent events through February 3, 2026, the date the consolidated financial statements were available to be issued and determined no additional subsequent events had occurred that would require disclosure in the consolidated financial statements, except as discussed below.

*Issuance of Convertible Promissory Notes* – During October and November 2025, the Company entered into convertible promissory notes for total proceeds of $3,030,000.

*Squeeze-Out Payment* – Immediately before the acquisition by ClearPoint Neuro, Inc. detailed below, the Company paid approximately $2,200,000 to complete the squeeze-out of the remaining minority shareholders of IRRAS AB.

*Acquisition by ClearPoint Neuro, Inc.* – On November 6, 2025, the Company entered into a Merger agreement with ClearPoint Neuro, Inc. ("ClearPoint") whereby ClearPoint acquired the Company in an all-stock and cash transaction. Under the terms of the agreement, the Company's stockholders will receive $5 million in cash and 1,325,000 shares of ClearPoint common stock at closing. As additional consideration for the Company's stockholders, the merger agreement provides for ClearPoint to pay earnout consideration during three one-year earnout periods equal to 25% of net sales of certain the Company's products above certain thresholds. All convertible notes and related interest noted above were automatically converted into common stock of IRRAS Holdings, Inc. immediately before the closing of the transaction.

------

## Exhibit 99.3

**Exhibit 99.3**

**UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL information**

**Introduction**

On November 20, 2025, ClearPoint Neuro, Inc. (the "Company" or "ClearPoint") completed its acquisition of IRRAS Holdings, Inc., a Delaware corporation ("IRRAS"), pursuant to the Agreement and Plan of Merger and Reorganization (the "Merger Agreement") with Ignite Merger Sub, Inc., a Delaware corporation and a direct wholly-owned subsidiary of the Company ("First Merger Sub"), ClearPoint Holdings, LLC, a Delaware limited liability company and a direct wholly-owned subsidiary of the Company ("Second Merger Sub"), IRRAS, the seller representative and the equity holders of IRRAS. Pursuant to the Merger Agreement, the First Merger Sub merged with and into IRRAS (the "First Merger"), with IRRAS surviving the First Merger, and, immediately following the First Merger, IRRAS merged with and into the Second Merger Sub (the "Second Merger" and together with the First Merger, the "Merger"), with the Second Merger Sub surviving the Second Merger.

The following unaudited pro forma condensed combined financial information has been prepared to illustrate the estimated effects of the Merger as if it had been consummated on September 30, 2025, for the purposes of the unaudited pro forma condensed combined balance sheet, and as if the Merger had been consummated on January 1, 2024, for purposes of the unaudited pro forma condensed combined statements of operations.

The unaudited pro forma condensed combined financial information was derived from, and should be read in conjunction with, the following historical financial statements and the accompanying notes, which are incorporated by reference into or attached as exhibits to the Current Report on Form 8-K/A to which this Exhibit 99.3 is attached (the "Form 8-K/A"):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•The historical audited consolidated financial statements of the Company as of and for the year ended December 31, 2024, as included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on February 26, 2025;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•The historical unaudited condensed consolidated financial statements of the Company as of and for the nine months ended September 30, 2025, as included in the Company's Quarterly Report on Form 10-Q filed with the SEC on November 6, 2025;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•The historical audited financial statements of IRRAS as of and for the year ended December 31, 2024, included as an exhibit to the Form 8-K/A; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•The historical unaudited consolidated financial statements of IRRAS as of and for the nine months ended September 30, 2025 and September 30, 2024, included as an exhibit to the Form 8-K/A.

The following unaudited pro forma condensed combined financial information has been prepared in accordance with Article 11of Regulation S-X and should be read in conjunction with the accompanying notes.

**Accounting for the Merger**

The unaudited pro forma condensed combined financial information has been prepared using the acquisition method of accounting in accordance with accounting principles generally accepted in the United States ("GAAP"). ClearPoint has been treated as the acquirer for accounting purposes, and thus accounts for the Merger as a business combination in accordance with Accounting Standards Codification Topic 805, Business Combinations ("ASC 805"). The total purchase price will be allocated to the tangible and intangible assets acquired and liabilities assumed based on their respective fair values. The assets and liabilities of IRRAS have been measured based on various preliminary estimates using assumptions that the Company's management believes are reasonable and based on currently available information. Accordingly, the pro forma adjustments are preliminary and have been made solely for the purpose of providing this unaudited pro forma condensed combined financial information.

Differences between these preliminary estimates and the final purchase accounting may occur, and the final purchase accounting could be materially different from the preliminary estimates used to prepare the accompanying unaudited pro forma condensed combined financial information and could have a material impact on the combined company's future results of operations and financial position.

**Basis of Pro Forma Presentation**

------

The unaudited pro forma condensed combined financial information appearing below does not consider any potential effects of changes in market conditions on revenues or expense efficiencies, among other factors. In addition, as explained in more detail in the accompanying notes, the preliminary allocation of the pro forma purchase price reflected in the unaudited pro forma condensed combined financial information is subject to adjustment and may vary significantly from what will be recorded upon completion of the final purchase price allocation.

The unaudited pro forma condensed combined financial information has been prepared based on the aforementioned historical financial statements and the assumptions and adjustments as described in the notes to the unaudited pro forma condensed combined financial information. The pro forma adjustments reflect transaction accounting adjustments related to the Merger, which are discussed in further detail below. Amounts presented reflect the accounting for the acquisition of IRRAS by ClearPoint. The unaudited pro forma condensed combined financial information and the related notes are presented for informational purposes only and do not reflect the costs of any integration activities or cost savings or synergies that may be achieved because of the Merger or represent or purport to represent actual financial positions or results of operations that the Company would have achieved had the companies been combined as of the dates or during the periods presented, nor do they represent or purport to represent any anticipated combined financial position or the future results of operations that the Company may achieve after acquisition.

The accounting policies followed in preparing the unaudited pro forma condensed combined financial statements are those used by ClearPoint as set forth in the audited historical financial statements. The unaudited pro forma condensed combined financial statements reflect any material adjustments known at this time to conform IRRAS historical financial information to ClearPoint's significant accounting policies based on the Company's initial review and understanding of IRRAS's significant accounting policies. A more comprehensive comparison and assessment will occur, which may result in additional differences being identified. Additionally, ClearPoint has included certain presentation adjustments for consistency in the financial statement presentation. See Notes 2 and 3 below for more information.

ClearPoint and IRRAS have not had any historical material relationship prior to the Merger. Accordingly, no pro forma adjustments were required to eliminate activities between the companies.

------

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Unaudited Pro Forma Condensed Combined Balance Sheet** | **Unaudited Pro Forma Condensed Combined Balance Sheet** | **Unaudited Pro Forma Condensed Combined Balance Sheet** | **Unaudited Pro Forma Condensed Combined Balance Sheet** | **Unaudited Pro Forma Condensed Combined Balance Sheet** | **Unaudited Pro Forma Condensed Combined Balance Sheet** | **Unaudited Pro Forma Condensed Combined Balance Sheet** |
| **As of September 30, 2025** | **As of September 30, 2025** | **As of September 30, 2025** | **As of September 30, 2025** | **As of September 30, 2025** | **As of September 30, 2025** | **As of September 30, 2025** |
| **(in thousands)** | **(in thousands)** | **(in thousands)** | **(in thousands)** | **(in thousands)** | **(in thousands)** | **(in thousands)** |
|  | **ClearPoint Historical** | **IRRAS<br> Historical** | **Presentation Adjustments** | **Transaction Accounting Adjustments** | **Financing Transaction Adjustments** | **Pro Forma Combined** |
| **ASSETS** |  |  |  |  |  |  |
| Current assets: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $38221 | $1349 |  | $(406) (C) |  | $56734 |
|  | - | - |  | (1848) (D) |  |  |
|  | - | - |  | (15) (B) |  |  |
|  | - | - |  |  | 19433<br> (F) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Current portion of restricted cash | - | 130 | (130) (A) |  |  | - |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | 4000 | 2132 |  |  |  | 6132 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventory, net | 6583 | 1404 |  | 627<br> (B) |  | 8614 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 2525 | 918 | 130<br> (A) |  |  | 3573 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 51329 | 5933 | - | (1642) | 19433 | 75053 |
| Property and equipment, net | 2114 | 54 |  |  |  | 2168 |
| Operating lease, right-of-use assets | 5955 | 3028 |  | (339) (B) |  | 8644 |
| Other assets | 959 | - | 740<br> (A) |  |  | 1699 |
| Restricted cash net of current portion | - | 740 | (740) (A) |  |  | - |
| Intangible assets, net | - | - |  | 15140<br> (B) |  | 15140 |
| Goodwill | - | - |  | 4511<br> (B) |  | 4511 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total assets | $60357 | $9755 | $- | $17669 | $19433 | $107214 |
| **LIABILITIES AND STOCKHOLDERS' EQUITY** |  |  |  |  |  |  |
| Current liabilities: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $723 | $988 |  |  |  | $1711 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued compensation | 3516 | - | 1603<br> (A) | 1384<br> (E) |  | 6503 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses and other current liabilities | - | 3827 | (3827) (A) |  |  | - |
| &nbsp;&nbsp;&nbsp;&nbsp;Other accrued liabilities | 1748 | - | 3827<br> (A) | (1848) (D) |  | 6174 |
|  | - | - | (1603) (A) | 3014<br> (B) |  |  |
|  | - | - |  | 828<br> (B) |  |  |
|  | - | - |  | 209<br> (B) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities, current portion | 347 | 427 |  | (286) (B) |  | 488 |
| &nbsp;&nbsp;&nbsp;&nbsp;Contract liabilities, current portion | 1719 | - | 47<br> (A) |  |  | 1766 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred Revenue | - | 47 | (47) (A) |  |  | - |

---

------

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;Convertible note at fair value | - | 10985 |  | (10985)(B) |  | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 8053 | 16274 | - | (7684) | - | 16642 |
| Operating lease liabilities, net of current portion | 6195 | 2755 |  | (207) (B) |  | 8743 |
| Contract liabilities, net of current portion | 769 | - |  |  |  | 769 |
| Long-term note payable, net | 29203 | - |  |  | 19433<br> (F) | 48636 |
| Other long-term liabilities | 263 | - |  |  |  | 263 |
| Deferred tax liabilities | - | - |  | 186<br> (B) | - | 186 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 44483 | 19029 | - | (7706) | 19433 | 75239 |
| Commitments and contingencies |  |  |  |  |  |  |
| Stockholders' equity: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Preferred stock | - | 2 |  | (2) (B) |  | - |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock | 284 | - |  |  |  | 297 |
|  | - | - |  | 13<br> (B) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 224714 | 105103 |  | (105103) (B) |  | 242592 |
|  | - | - |  | 17878<br> (B) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive (loss) income | - | 525 |  | (525) (B) |  | - |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit | (209124) | (112576) |  | 112576<br> (B) |  | (210914) |
|  | - | - |  | (1384) (E) |  |  |
|  | - | - |  | (406) (C) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Noncontrolling interest | - | (2328) |  | 2328<br> (B) |  | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 15874 | (9274) | - | 25375 | - | 31975 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $60357 | $9755 | $- | $17669 | $19433 | $107214 |

---

------

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Unaudited Pro Forma Condensed Combined Statement of Income** | **Unaudited Pro Forma Condensed Combined Statement of Income** | **Unaudited Pro Forma Condensed Combined Statement of Income** | **Unaudited Pro Forma Condensed Combined Statement of Income** | **Unaudited Pro Forma Condensed Combined Statement of Income** | **Unaudited Pro Forma Condensed Combined Statement of Income** | **Unaudited Pro Forma Condensed Combined Statement of Income** |
| **For the Nine Months Ended September 30, 2025** | **For the Nine Months Ended September 30, 2025** | **For the Nine Months Ended September 30, 2025** | **For the Nine Months Ended September 30, 2025** | **For the Nine Months Ended September 30, 2025** | **For the Nine Months Ended September 30, 2025** | **For the Nine Months Ended September 30, 2025** |
| **(in thousands, except for share and per share amounts)** | **(in thousands, except for share and per share amounts)** | **(in thousands, except for share and per share amounts)** | **(in thousands, except for share and per share amounts)** | **(in thousands, except for share and per share amounts)** | **(in thousands, except for share and per share amounts)** | **(in thousands, except for share and per share amounts)** |
|  | **ClearPoint Historical** | **IRRAS<br> Historical** | **Presentation Adjustments** | **Transaction Accounting Adjustments** | **Financing Transaction Adjustments** | **Pro Forma Combined** |
| Revenue: |  |  |  |  |  |  |
| &nbsp;&nbsp;Product revenue | $16649 | $6789 |  |  |  | $23438 |
| &nbsp;&nbsp;Service and other revenue | 9912 | - |  |  |  | 9912 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total revenue | 26561 | 6789 | - | - | - | 33350 |
| Cost of revenue | 10273 | 3046 | 93<br> (AA) | 971<br> (BB) |  | 14383 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 16288 | 3743 | (93) | (971) | - | 18967 |
| Research and development costs | 10660 | 2694 |  |  |  | 13354 |
| Sales and marketing expenses | 11691 | 6280 |  | 619<br> (BB) |  | 18590 |
| General and administrative expenses | 11056 | 2620 | (93) (AA) |  |  | 13583 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating loss | (17119) | (7851) | - | (1590) | - | (26560) |
| Other income (expense): |  |  |  |  |  |  |
| &nbsp;&nbsp;Other income (expense), net | (112) | 171 |  | (220) (DD) |  | (161) |
| &nbsp;&nbsp;Interest income | - | 30 | (30) (AA) |  |  | - |
| &nbsp;&nbsp;Interest expense | - | (313) | 313<br> (AA) |  |  | - |
| &nbsp;&nbsp;Interest (expense) income, net | (472) | - | (283) (AA) | 283<br> (DD) | 1654<br> (GG) | 1182 |
| Net loss before income taxes | (17703) | (7963) | - | (1527) | 1654 | (25539) |
| &nbsp;&nbsp;Income tax (expense) benefit | (51) | (1) |  | <br> (EE) | - | (52) |
| Net loss | $(17754) | $(7964) | $- | $(1527) | $1654 | $(25591) |
| Net loss per share attributable to common stockholders: |  |  |  |  |  |  |
| &nbsp;&nbsp;Basic and diluted | $(0.63) |  |  |  |  | $(0.87) |
| Weighted average shares outstanding: |  |  |  |  |  |  |
| &nbsp;&nbsp;Basic and diluted | 28137528 |  |  |  |  | 29461932 |

---

------

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Unaudited Pro Forma Condensed Combined Statement of Income** | **Unaudited Pro Forma Condensed Combined Statement of Income** | **Unaudited Pro Forma Condensed Combined Statement of Income** | **Unaudited Pro Forma Condensed Combined Statement of Income** | **Unaudited Pro Forma Condensed Combined Statement of Income** | **Unaudited Pro Forma Condensed Combined Statement of Income** | **Unaudited Pro Forma Condensed Combined Statement of Income** |
| **For the Year Ended December 31, 2024** | **For the Year Ended December 31, 2024** | **For the Year Ended December 31, 2024** | **For the Year Ended December 31, 2024** | **For the Year Ended December 31, 2024** | **For the Year Ended December 31, 2024** | **For the Year Ended December 31, 2024** |
| **(in thousands, except for share and per share amounts)** | **(in thousands, except for share and per share amounts)** | **(in thousands, except for share and per share amounts)** | **(in thousands, except for share and per share amounts)** | **(in thousands, except for share and per share amounts)** | **(in thousands, except for share and per share amounts)** | **(in thousands, except for share and per share amounts)** |
|  | **ClearPoint Historical** | **IRRAS<br> Historical** | **Presentation Adjustments** | **Transaction Accounting Adjustments** | **Financing Transaction Adjustments** | **Pro Forma Combined** |
| Revenue: |  |  |  |  |  |  |
| &nbsp;&nbsp;Product revenue | $18626 | $5490 |  |  |  | $24116 |
| &nbsp;&nbsp;Service and other revenue | 12764 | - |  |  |  | 12764 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total revenue | 31390 | 5490 | - | - | - | 36880 |
| Cost of revenue | 12268 | 2637 | 38<br> (AA) | 1921<br> (BB) |  | 16864 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 19122 | 2853 | (38) | (1921) | - | 20016 |
| Research and development costs | 12392 | 2464 |  |  |  | 14856 |
| Sales and marketing expenses | 14478 | 6486 |  | 825<br> (BB) |  | 21789 |
| General and administrative expenses | 11940 | 3447 | (38) (AA) | 406<br> (CC) |  | 17139 |
|  | - | - |  | 1384<br> (FF) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating loss | (19688) | (9544) | - | (4536) | - | (33768) |
| Other income (expense): |  |  |  |  |  |  |
| &nbsp;&nbsp;Other income (expense), net | (40) | (210) | - | 220<br> (DD) |  | (30) |
| &nbsp;&nbsp;Interest income | - | 110 | (110) (AA) |  |  | - |
| &nbsp;&nbsp;Interest expense | - | (70) | 70<br> (AA) |  |  | - |
| &nbsp;&nbsp;Interest (expense) income, net | 872 | - | 40<br> (AA) | 70<br> (DD) | 2206<br> (GG) | 3188 |
| Net loss before income taxes | (18856) | (9714) | - | (4246) | 2206 | (30610) |
| &nbsp;&nbsp;Income tax (expense) benefit | (58) | (11) |  | <br> (EE) |  | (69) |
| Net loss | $(18914) | $(9725) | $- | $(4246) | $2206 | $(30679) |
| Net loss per share attributable to common stockholders: |  |  |  |  |  |  |
| &nbsp;&nbsp;Basic and diluted | $(0.70) |  |  |  |  | $(1.08) |
| Weighted average shares outstanding: |  |  |  |  |  |  |
| &nbsp;&nbsp;Basic and diluted | 27027692 |  |  |  |  | 28352096 |

---

------

**NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS**

**1. Basis of Presentation** 

The pro forma adjustments have been prepared as if the Merger had been consummated on September 30, 2025, in the case of the unaudited pro forma condensed combined balance sheet, and, in the case of the unaudited pro forma condensed combined statements of operations, as if the Merger had been consummated on January 1, 2024, the beginning of the earliest period presented in the unaudited pro forma condensed combined statements of income.

The unaudited pro forma condensed combined financial information has been prepared assuming the acquisition method of accounting in accordance with GAAP. Under this method, IRRAS's assets and liabilities will be recorded at their respective fair values. Any difference between the purchase price for IRRAS and the fair value of the identifiable net assets acquired (including intangibles) will be recorded as goodwill. The pro forma adjustments are based on preliminary accounting conclusions and are subject to potential revisions upon further analysis.

The pro forma adjustments represent management's estimates based on information available as of the date of this Form 8-K/A and are subject to change as additional information becomes available and additional analyses are performed.

One-time direct and incremental transaction costs have been expensed as incurred under ASC 805.

ClearPoint has performed a preliminary review to identify any accounting policy differences between the accounting policies used in IRRAS's financial statements and those of the Company, where the impact was potentially material and could be reasonably estimated, with the Company identifying no such differences.

**2. Adjustments to the Unaudited Pro Forma Condensed Combined Balance Sheet as of September 30, 2025**

The adjustments included in the unaudited pro forma condensed combined balance sheet as of September 30, 2025 are as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)Reflects reclassification adjustments to conform IRRAS's historical balances to the financial statement presentation of ClearPoint.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)Reflects the purchase price allocation adjustments to record IRRAS's assets and liabilities at estimated fair value based on the consideration conveyed. The related income statement adjustments are reflected at adjustment (BB). Additionally, this adjustment reflects the recording of the preliminary estimate of goodwill and the elimination of the historical equity balances of IRRAS.

The preliminary purchase price was allocated among the identified assets to be acquired, based on a preliminary analysis. Goodwill is expected to be recognized as a result of the Merger, which represents the excess fair value of consideration over the fair value of the underlying net assets of IRRAS. This was considered appropriate based on the determination that the Merger would be accounted for as a business acquisition under ASC 805. The deferred income taxes represent the deferred tax impact associated with the incremental differences in book and tax basis created from the preliminary purchase price allocation. Deferred taxes associated with estimated fair value adjustments were calculated using the statutory tax rate of 21%. The estimates of fair value are based upon preliminary valuation assumptions, and are believed to be reasonable, but are inherently uncertain and unpredictable. As a result, actual results may differ from estimates, and the difference may be material.

The following is a preliminary estimate of the assets acquired and the liabilities assumed by ClearPoint in the Merger, reconciled to the estimated purchase consideration (in thousands):

------

---

| | |
|:---|:---|
| **Net Assets Identified** | **Preliminary Estimate of Fair Value** |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $1349 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | 2132 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventory, net | 2031 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 1048 |
| &nbsp;&nbsp;&nbsp;&nbsp;Property and equipment, net | 54 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease, right-of-use assets | 2689 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other assets | 740 |
| &nbsp;&nbsp;&nbsp;&nbsp;Intangible assets, net <sup>(1)</sup> | 15140 |
| &nbsp;&nbsp;&nbsp;&nbsp;Goodwill | 4511 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | (988) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued compensation | (1603) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other accrued liabilities | (6273) |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities, current portion | (141) |
| &nbsp;&nbsp;&nbsp;&nbsp;Contract liabilities, current portion | (47) |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities, net of current portion | (2548) |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | (186) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total Fair Value** | $17908 |
| **Purchase Consideration** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity Consideration <sup>(2)</sup> | $17893 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash Consideration <sup>(3)(4)</sup> | 15 |
|  | $17908 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)Intangible assets were comprised of the following:

---

| | | | |
|:---|:---|:---|:---|
| **Asset type** | **Fair Value** | **Useful Life** | **Valuation methodology** |
| &nbsp;&nbsp;&nbsp;&nbsp;Developed Technology | $12940 | 10 years | Multi-Period Excess Earnings Method |
| &nbsp;&nbsp;&nbsp;&nbsp;Customers relationships | 1650 | 6 years | Distributor Method |
| &nbsp;&nbsp;&nbsp;&nbsp;Trademark/Trade Name | 550 | 1 year | Relief from Royalty |
| **Total intangible assets** | $15140 |  |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)Equity consideration was provided in the form of issuance of common stock, adjustment holdback shares and indemnification holdback shares and was calculated as 1.3 million shares of ClearPoint common stock to be issued to IRRAS shareholders, 0.015 million holdback shares and 0.2 million indemnification shares multiplied by $13.51, the closing share price of ClearPoint on November 20, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)Reflects the cash consideration paid at closing for outstanding vested stock options of $0.02 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)Management concluded the fair value of the contingent earnout is immaterial as of the acquisition date because the sales-based milestones are not probable; accordingly, no contingent consideration liability is reflected in the unaudited pro forma financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)Reflects the impact of nonrecurring expenses related to estimated transaction costs, primarily comprised of legal fees and other related advisory costs. The related income statement adjustment is reflected at adjustment (CC).

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D)Reflects the impact of nonrecurring payment related to assumed legal fees, tax obligations, and audit fee accruals.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(E)Reflects post-closing severance paid by the acquiree to certain executives totaling $1.3 million. The amount was determined to benefit the Company and, accordingly, was recognized as compensation expense in the combined Company financial statements. The related income statement adjustment is reflected at adjustment (FF).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(F)In connection with the Transaction, the Company entered into an agreement to access an additional $20.0 million in funding under its existing credit facility and borrowed $19.4 million, net of issuance costs. The related cash inflow and increase in long-term debt are reflected in the unaudited pro forma condensed balance sheet as of September 30, 2025.

**3. Adjustments to the Unaudited Pro Forma Condensed Combined Statement of Income for the Nine Months ended September 30, 2025 and for the Year ended December 31, 2024**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(AA) Reflects reclassification adjustments to conform IRRAS's historical balances to the financial statement presentation of ClearPoint.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(BB) Reflects the pro forma impacts related to the purchase price allocation discussed at adjustment (B). This includes the following impacts:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•*Amortization expense on intangible assets* - Reflects an increase in amortization expense in the amount of $1.6 million for the nine months ended September 30, 2025 and an increase of $2.1 million for the year ended December 31, 2024. This change related to developed technology, customer relationships and trade names and was calculated using the estimated weighted average remaining useful life of 10 years, 6 years and 1 year respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•*Fair value of inventory* – Reflects an increase in the carrying amount of inventory of $0.7 million for the year ended December 31, 2024, with a corresponding increase to cost of revenue of $0.7 million in the same period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(CC) Reflects the impact of nonrecurring expenses related to estimated transaction costs, primarily comprised of legal fees and other related advisory costs.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(DD) Reflects the elimination of historical interest expense and change in fair value of convertible promissory notes. The related balance sheet adjustment is reflected at adjustment (B).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(EE) The Company maintains a full valuation allowance for the periods presented; accordingly, no incremental income tax expense or benefit is recognized, as the consolidated entity is currently in a net operating loss (NOL) position.

('FF) Reflects the impact of post-closing severance paid to certain executives of the acquiree in the amount of $1.3 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(GG) Reflects the interest expense in the amount of $1.7 million for the nine months ended September 30, 2025 and $2.2 million for the period ended December 31, 2024 associated with the $19.4 million of indebtedness incurred in connection with the Transaction.

**4. Unaudited Pro Forma Net Loss Per Share**

The pro forma net loss per share calculations have been performed for the nine months ended September 30, 2025 and for the year ended December 31, 2024, assuming the Merger occurred on January 1, 2024.

------

---

| | | |
|:---|:---|:---|
|  | **For the Nine Months Ended** | **For the Year Ended** |
|  | **September 30, 2025** | **December 31, 2024** |
| **Numerator (in thousands)** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Pro forma net income | $(25591) | $(30679) |
| **Denominator** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;ClearPoint pro forma weighted average shares of common stock outstanding | 28137528 | 27027692 |
| &nbsp;&nbsp;&nbsp;&nbsp;Add: Shares issued to IRRAS shareholders | 1324404 | 1324404 |
| &nbsp;&nbsp;&nbsp;&nbsp;Pro forma weighted average shares of common stock outstanding - basic & diluted | 29461932 | 28352096 |
| **Pro forma earnings per share - basic & diluted** | $(0.87) | $(1.08) |

---

The Company's common stock equivalents are excluded from the computation of diluted pro forma earnings per share as the shares would have been antidilutive.

------